China BCI industry deep-dive: TechCrunch confirms eight major Chinese BCI companies racing from research to scale with policy tailwind
Summary
TechCrunch published a comprehensive analysis in February 2026 confirming that China's BCI industry is rapidly moving from research to commercialization. The eight most active players identified: NeuroXess, Neuracle, NeuralMatrix, BrainCo, Bo Rui Kang Tech, Aoyi Tech, Brainland Tech, and Zhiran Medical — spanning implantable flexible interfaces to non-invasive approaches. Structural policy advantages: provinces Sichuan, Hubei, and Zhejiang have already set medical service pricing for BCI, speeding its inclusion in the national medical insurance system. China's BCI market expected to grow to $530M+ (¥3.8B) in 2025, up from ¥3.2B in 2024. Following Neuracle NEO's NMPA commercial approval on March 13, 2026 — the world's first commercial BCI approval — the policy and market momentum is accelerating.
Why it matters
Eight competitive Chinese BCI companies with provincial insurance pricing and a commercial product already approved is the clearest possible evidence that China has built a self-sustaining BCI ecosystem, not just a handful of showcase companies. The three provinces that have already set BCI medical service pricing effectively created regional commercial BCI markets before national coverage — a bottom-up commercialization strategy that bypasses the slow top-down regulatory process that limits US BCI adoption.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial